Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage |
| |
| Affiliation: | 1. Head Respiratory Medicine and Research Centre on Asthma and COPD, University of Ferrara, Ferrara, Italy;2. Department of Pathophysiology and Transplantation, University of Milan, IRCCS Fondazione Cà Granda, Milano, Italy;3. Allergy and Respiratory Disease Clinic, University of Genova, Genova, Italy;4. Unit of Respiratory Clinical Pharmacology, Department of System Medicine, University of Rome Tor Vergata, Roma, Italy;5. Respiratory Unit, San Paolo Hospital, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy;6. Department of Medical and Surgical Sciences University of Foggia, Foggia, Italy;7. Respiratory Pathophysiology, Cardiothoracic Dept., University Hospital, Siena, Italy;8. Respiratory Pathophysiology and Rehabilitation Unit, Cardio-Thoracic and Vascular Department, University of Pisa, Pisa, Italy;9. Department of Clinical and Biological Sciences, University of Torino, Torino, Italy;10. Pulmonary Unit, Department of Medicine, University of Verona, Verona, Italy;11. Department of Medicine, Section of Pulmunology, University of Palermo, Palermo, Italy;1. IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, via Giuseppe La Masa 19, 20156 Milano, Italy;2. European Clinical Research Infrastructure Network, Biopark, 5-7 rue Watt 75013 Paris, France;3. The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;4. Coordination Centre for Clinical Trials, Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225 Düsseldorf, Germany;1. Gastroenterology Service, ASL BAT, Andria, BT, Italy;2. Division of Gastroenterology, ASL Roma H, Albano Laziale, Rome, Italy;3. Division of Surgery, “P. Colombo” Hospital, Velletri, Rome, Italy;4. Division of Gastroenterology, “San Paolo” Hospital, Bari, Italy;5. Division of Gastroenterology, “Cristo Re” Hospital, Rome, Italy;6. Digestive Endoscopy Unit, “Santa Maria Goretti” Hospital, Latina, Italy;7. Digestive Endoscopy and Nutrition Unit, “S. Eugenio” Hospital, Rome, Italy;8. Division of Gastroenterology, “Belcolle Hospital”, Viterbo, Italy |
| |
| Abstract: | International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment.Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristics meet the recommendations of international guidelines, and the preferences of respiratory physicians who identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
